NCT07156604View on ClinicalTrials.gov

Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2030

Conditions
NSCLCNeoadjuvant Therapy
Interventions
DRUG

Vebreltinib Enteric Capsules

treated with Vebreltinib (200 mg bid po) for 8 weeks before surgery.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai,, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER

NCT07156604 - Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter